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We present an approach integrating structural and
computational biology with immunological tests
to identify epitopes in the OppA antigen from the
Gram-negative pathogen Burkholderia pseudomal-
lei, the etiological agent of melioidosis. The crystal
structure of OppABp, reported here at 2.1 A˚ resolu-
tion, was the basis for a computational analysis
that identified three potential epitopes. In parallel,
antigen proteolysis and immunocapturing allowed
us to identify three additional peptides. All six poten-
tial epitopes were synthesized as free peptides
and tested for their immunoreactivity against sera
from healthy seronegative, healthy seropositive,
and recovered melioidosis patients. Three synthetic
peptides allowed the different patient groups to
be distinguished, underlining the potential of this
approach. Extension of the computational analysis,
including energy-based decomposition methods,
allowed rationalizing results of the predictive anal-
yses and the immunocapture epitope mapping.
Our results illustrate a structure-based epitope dis-
covery process, whose application may expand our
perspectives in the diagnostic and vaccine design
fields.
INTRODUCTION
Structure-based antigen design is emerging as a strategy for
next-generation vaccine development (Dormitzer et al., 2008).
This approach enables antigens to be discovered and engi-
neered for improved biochemical and immunological properties,
to enhance vaccine efficacy, possibly generating cross-reactive
vaccines whenmicrobial antigenic variation is a factor (DormitzerStructure 21, 16et al., 2008; Schneewind andMissiakas, 2011). Its prerequisite is
a detailed knowledge of the three-dimensional (3D) structure of
an antigenic protein, which provides atomic-level information
on the overall antigen fold and epitope location/formation.
Complemented by computational analyses, the conformational
properties of the antigen and the molecular determinants of
antibody recognition may be further probed to facilitate the
engineering process. An elegant use of computer-aided struc-
ture-based design is illustrated by the grafting of the typically
transient HIV-1 gp41 neutralizing epitope onto a more stable
protein backbone scaffold (Ofek et al., 2010). Nevertheless,
despite some successful examples (Nuccitelli et al., 2011), the
whole field is still largely in its early development stages.
Melioidosis vaccine research has been intensely pursued over
the last decade in the therapeutic and also biodefense areas
(inhalation is a principal infection route of B. pseudomallei).
This intracellular Gram-negative bacterium is endemic in tropical
areas of Southeast Asia and Northern Australia (Currie et al.,
2008). Because of the polymorphic nature of B. pseudomallei
infections, translating into symptoms mimicking different
diseases, and due to its multidrug resistance, B. pseudomallei
proves itself difficult to diagnose and treat (Cheng and Currie,
2005). Early diagnosis, coupled to vaccination, would accelerate
and improve melioidosis treatment, with a vaccine being a
cost-effective alternative to antibiotic administration, preventing
both relapse and reinfection; however, all potential melioidosis
vaccines tested to date have proven unsuccessful (Sarkar-Tyson
and Titball, 2010).
A recent study launched to investigate the interaction of the
host immune system with B. pseudomallei used a protein micro-
array, covering over 1,000 proteins, to probe for immunoreac-
tivity against melioidosis patient sera, producing a short list of
49 antigens that were significantly reactive in comparison with
sera from healthy individuals (Felgner et al., 2009). Several anti-
gens were further studied for their immunogenic properties,
including the oligopeptide-binding protein A (OppABp), which is
the focus of this communication. OppABp is part of an ATP-
binding cassette (ABC) transport system, a group of proteins7–175, January 8, 2013 ª2013 Elsevier Ltd All rights reserved 167
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interventions against bacterial infections, given their key role in
bacterial survival, virulence, and pathogenicity. Components of
several ABC transporter systems, from both Gram-negative
and Gram-positive bacteria, have been proposed as candidates
for vaccine development because they were shown to react with
convalescent patient sera (Garmory and Titball, 2004; Tanabe
et al., 2006).
OppA is part of the oligopeptide transport system OppABCDF
involved in nutrient uptake and recycling of cell-wall peptides
(Monnet, 2003). The transport system consists of five subunits:
two integral membrane proteins forming the pore, two proteins
responsible for ATP hydrolysis, and a substrate-binding protein
(SBP) (Monnet, 2003). OppA is a receptor, or SBP, and deter-
mines the recognition properties of the system, delivering the
substrates to its cognate-binding partners. Precedent studies
on OppA from different pathogens revealed that OppA from
Listeria monocytogenes is a virulence factor important for
intracellular survival (Borezee et al., 2000) and that OppA from
Yersinia pestis is a protective antigen (Tanabe et al., 2006).
With regard to OppABp, it is recognized by T cells primed by
B. pseudomallei, triggers IFN-g production, and stimulates
both humoral and cell-mediated responses. However, sera
raised against OppABp failed to offer protection in a mouse
infection model (Harland et al., 2007). Therefore, OppABp is
seen as a suitable target for structure-based antigen analysis
and improvement of its antigenic properties.
In this framework, we studied the crystal structure of OppABp
(at 2.1 A˚ resolution), which was used as a template for com-
putational epitope design/predictions using matrix of local
coupling energies (MLCE) (Scarabelli et al., 2010) and electro-
static desolvation profiles (EDP) (Fiorucci and Zacharias, 2010)
methods, resulting in the identification of three consensus
peptides (COMP1–COMP3). In parallel, we performed experi-
mental epitope mapping, based on proteolytic digestion of
OppABp and immunocapture of peptide fragments containing
the epitopes recognized by murine anti-OppABp polyclonal anti-
bodies, which provided three potential epitope sequences
(EXP4–EXP6). The COMP and EXP peptides were synthesized
and tested for their immunoreactivity against sera from unin-
fected, healthy-infected, and melioidosis-recovered patients.
Plasma antibodies from patients who had recovered from
B. pseudomallei infection significantly recognized all COMP
peptides and EXP4, relative to plasma antibodies from the
seronegative group. Human plasma antibodies recognizing all
peptides but COMP2 were significantly higher in the healthy
seropositive group than in the seronegative one. Interestingly,
antibodies recognizing EXP5 and EXP6 were also significantly
higher in the healthy seropositive group than in the recovered
melioidosis groups. It is also remarkable that response to
COMP3 was significantly different in all three groups. Com-
parison of experimental and computational results led us to
further develop our in silico epitope prediction methods, by
incorporating an energy-based decomposition approach to
divide the antigenic protein into fragments prior to MLCE and
EDP analyses. Such an approach was instrumental in improving
the agreement between structure-based epitope predictions
and immunocapture epitope mapping. Our results highlight
the potential of a structure-to-epitope prototypic pipeline that168 Structure 21, 167–175, January 8, 2013 ª2013 Elsevier Ltd All rigcombines structural and computational biology, to identify
antigenic substructures/epitopes in view of their application in
diagnostic tools or vaccine development.
RESULTS
3D Structure of OppABp
The OppABp gene (GeneDB code BPSS2141) encoding for
protein residues 39–554, devoid of its predicted signal peptide
(residues 1–38), was amplified, cloned in pET14b, and ex-
pressed in BL21 Star (DE3) Escherichia coli cells; the protein
construct was purified as a N-terminal His-tag fusion protein
and crystallized. The crystal structure of OppABp was solved at
a resolution of 2.1 A˚ (Rgen and Rfree values of 15.8% and
20.9%, respectively), as described in the Experimental Proce-
dures (statistics for the data collection and model refinement
are shown in Table 1). Electron density was visible for residues
48–553 but absent for the first 30 N-terminal residues (21 corre-
sponding to the His-tag region and 9 to the protein) and for the
C-terminal residue 554. The 3D structures of several oligopep-
tide-binding proteins have been previously reported by Bernts-
son et al. (2009), Dunten and Mowbray (1995), Levdikov et al.
(2005), Sleigh et al. (1999), Tanabe et al. (2007). Despite low
sequence similarity, superimposition of the C-a backbones
(http://bioinfo3d.cs.tau.ac.il/c_alpha_match/) highlighted sig-
nificant structure conservation between OppABp and the six
OppA homologs, with rmsd values in the 1.1–1.9 A˚ range.
All OppAs consist of two main domains, with the polypeptide
chain crossing over between the two domains, two or three
times, resulting in the formation of a hinge that opens and closes
upon ligand binding and release. Indeed, OppABp is composed
of two lobes (domains AB and C) comprising a/b folds, con-
nected by two loops (residues 299–307 and 521–528), which
form the hinge (Figure 1). Domain AB is formed by the N and
C termini regions (residues 48–303 and 524–553, respectively),
whereas domain C is formed by an internal contiguous segment
(residues 304–523). Domain C has an a/b topology, in which a
central mixed b sheet (b17-b12-b16) is flanked by eight a helices
and a b sheet (b14–b15) (Figure 1). Domain AB can be further
divided into two subdomains, with subdomain A hosting the
N- and C-terminal parts of the protein (residues 48–264 and
541–553) and presenting an a/b fold. Subdomain B (residues
265–303 and 524–540), linked to domain C, consists mostly of
meandering loops with small b strands (b18, b19, and b20) and
two parallel a helices (a6 and a7). We observed the presence
of a disulphide bond (between C469 and C479) in domain C of
OppABp, a variable feature among OppA family members that
contributes to formation of the substrate-binding site.
OppAs bind small peptides with high affinity without any
sequence specificity, which explains why they are often copuri-
fied with their bound peptide, as seen for OppABp. Subdomain
A and domain C form the ligand-binding pocket. Based on elec-
tron density fitting, we assigned the sequence D-V-A to the
tripeptide, which binds as reported for OppA from Salmonella
typhimurium (Sleigh et al., 1999).
Epitope Prediction and Design of Antigenic Peptides
Two different epitope prediction computational methods were
combined and applied to representative structures obtainedhts reserved
Table 1. Data Collection and Refinement Statistics for OppABp
OppABp (Residues 48–553)
Data Collection
Space group P21
Cell dimensions
a, b, c (A˚) 46.9, 81.9, 74.2
a, b, g () 90, 104.3, 90
Resolution (A˚) 40.97–2.1 (2.21–2.1)
Rmerge
a 0.089 (0.287)
I/sIa 13.2 (5.6)
Completeness (%)a 99.96 (99.87)
Redundancya 4.5 (4.5)
Refinement
Resolution (A˚) 38.5–2.1
No. of reflections 31,796
Rgen/Rfree 15.8/20.9
No. of atoms
Protein 4,060
Peptide 22
Water 221
Glycerol 56
Chloride ion 1
B factors (A˚2)
Protein 22.9
Ligand 22.8
Water 26.2
Glycerol 61.1
Chloride ion 27.8
Rmsds
Bond lengths (A˚) 0.006
Bond angles () 0.909
Ramachandran plot (%)
Favored regions 98.4
Allowed regions 1.6
A single data collection was allowed to solve the structure. Rmerge =P
rI(I)rP I 3 100, where I is the intensity of a reflection, and (I) is the
average intensity; Rfree was calculated from 5% of randomly selected
data for cross-validation; R factor =
P
rFoFcr/
P
rFor 3 100.
aValues in parentheses are for the highest-resolution shell.
Structure
Epitope Discovery for Structural Vaccinologyfrom molecular dynamics (MD) simulations run on the OppABp
crystal structure (see Experimental Procedures) (Fiorucci and
Zacharias, 2010; Scarabelli et al., 2010). MLCE was specifically
developed to pick antigenic epitopes, whereas the scope of
EDP is broader, having been developed to identify general
protein-protein interaction interfaces and also being validated
for antigen-antibody interactions. The prediction results individ-
ually produced by MLCE and EDP, with regard to the protein
sequence, are presented in Figure S2, which is available online.
Consensus analysis of the results from the two methods led to
the identification of three different minimal epitopes, labeled
COMP1–COMP3, which are displayed on the OppABp 3D struc-
ture (Figure 2).Structure 21, 16COMP1 is a conformational epitope, composed of two loops
(residues A107–D109 and T185–P188), COMP2 is a polypeptide
segment devoid of secondary structure that extends from R363
to P367, and COMP3 corresponds to a highly solvent-accessible
area on the protein surface, comprising the most exposed resi-
dues of the N480–L509 stretch. The conformational properties
of the predicted epitopes were further characterized through
MD simulations (see Supplemental Experimental Procedures;
Figure S1), with COMP1 and COMP2 being flexible and
COMP3 maintaining its conformation with minor fluctuations.
Experimental Epitope Mapping
Epitope mapping experiments were carried out using recombi-
nant OppABp and cognate polyclonal sera. To this aim, we adop-
ted and extended an immunocapturing approach successfully
used previously with monoclonal antibodies (Koehler et al.,
2011; Soriani et al., 2010). The approach involves proteolytic
digestion (using diverse proteases) of the target antigen prior
to immunocapturing and subsequent analysis of antibody-
bound peptides (containing epitopes or fragments thereof) by
mass spectrometry. The sera collected from three immunized
mice were independently analyzed and produced identical
results. Using trypsin for the partial digestion of OppABP, four
different peptides were captured by the polyclonal IgGs, with
masses of 1768.909, 1991.121, 2096.056, and 2638.095 Da.
MS/MS analysis of the 1768.909 Da peptide showed that it
corresponded to the N-terminal His-tag segment 2-GSSHHH
HHHSSGLVPR-17 (1767.841 Da). The other three peptides cor-
responded to the sequences 121-WSNGQPVTAADFVYAWQR-
138 (peptide EXP4, 2096.056 Da), 299-ELRPGLQLATYYYYLK-
314 (EXP5, 1991.121 Da), and 336-EILTSKITQAGEVPM(oxy)
YGLM(oxy)PKGVK-359 (EXP6, 2638.095 Da; M(oxy) standing
for oxidized methionine).
Synthesis of Epitope Peptides
The results of the structure-based predictions were used to
design and synthesize a set of polypeptides corresponding to
the selected epitope regions,with different supporting tags (using
two polyethylene glycol [PEG] moieties as spacers and human
serum albumin [HSA] as a carrier protein) (see Experimental
Procedures). The final peptide sequences were HSA-Cys-PEG-
PEG-KAPDTggKTEVPVSY (COMP1); HSA-Cys-PEG-PEG-GVK
GVQRPFTPDWA (COMP2); HSA-Cys-PEG-PEG-AEANQKLDD
GARAALLTQAHDLA (COMP3); HSA-Cys-PEG-PEG-WSNGQPV
TAADFVYAWQR (EXP4); HSA-Cys-PEG-PEG- ELRPGLQLATYY
YYLK (EXP5); and HSA-Cys-PEG-PEG-EILTSKITQAGEVPMYGL
MPKGVK (EXP6). COMP1 is a conformational epitope: the intro-
duction of two glycine residues (lowercase residues in the
sequence) was estimated to be sufficient to mimic the distance
between the two termini and theorientationof the twoconstituting
stretches observed in the crystal structure. The computationally
predicted epitope residues are underlined.
Peptide Detection by Human Plasma Antibodies
To evaluate their immunogenicity, the synthetic peptides were
tested for antibody recognition in plasma samples from 19
healthy donors and 20 recovered melioidosis cases (from
Khon Kaen University and Srinakarin Hospital, Thailand), by indi-
rect ELISA. Healthy donors were divided into two groups,7–175, January 8, 2013 ª2013 Elsevier Ltd All rights reserved 169
Figure 1. Tertiary Structure of OppABp
Secondary structure ribbon representation of
OppABp bound to its tripeptide ligand (purple ball
and stick). Domains AB and C are illustrated in
yellow-red and green, respectively. b Strands,
a helices, and 310 helices are labeled S1–S17,
H1–H15, and h1–h7, respectively. The N and
C termini (N term and C term, respectively) of
OppABp are labeled. This figure was generated
using PyMOLWin.
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hemagglutinin assay (IHA) antibody titers (see Supplemental
Experimental Procedures). As expected, control experiments
showed that plasma antibodies to a crude B. pseudomallei
antigen extract (Figure 3A) and to recombinant OppABp (Fig-
ure 3B) in seropositive and recovered groups were significantly
higher than those in the seronegative group (Mann-Whitney
U test; p < 0.001 and p < 0.05, respectively). Interestingly, the
average response of recovered plasma antibodies recognizing
our recombinant OppABp was much higher than previously re-
ported by Suwannasaen et al. (2011).
Parallel experiments with the COMP1–COMP3 peptides re-
vealed that the recovered group generally showed higher reac-
tivity against all three peptides, as compared to the seronegative
group (Mann-Whitney U test; p < 0.05, p < 0.01, and p < 0.01, for
COMP1, COMP2, and COMP3, respectively; Figures 3C–3E).
In addition, COMP1 and COMP3 peptides were significantly
recognized by plasma from seropositive subjects (Mann-
Whitney U test; p < 0.05) that were classified as asymptomatic
healthy control subjects (subclinical melioidosis), compared to
seronegative plasma samples (Figures 3C and 3E). Interestingly,
the reactivity of COMP3 was significantly diverse among the
three groups (Figure 3E), highlighting its potential use as a diag-
nostic tool.
The EXP4–EXP6 peptides showed a distinct reactivity pattern
toward plasma of all three groups (Figures 3F–3H). In fact, the
EXP peptides reacted strongly with the plasma from asymp-
tomatic healthy patients relative to the healthy individuals.
Particularly, the EXP5 and EXP6 were not significantly recog-
nized by the plasma from recovered subjects, hinting at the
potential application of both peptides for discriminating
between asymptomatic versus clinical melioidosis in endemic
areas (Figures 3G and 3H). Thus, the results obtained confirm170 Structure 21, 167–175, January 8, 2013 ª2013 Elsevier Ltd All rights reservedthat the peptides were recognized by
the humoral-mediated immune response
to B. pseudomallei infection in humans.
In Silico Fragment Subdivision
Coupled to Epitope Prediction
The identification of distinct sets of
epitopes by the computational approach
(COMP1–COMP3) and by the polyclonal
antibodies induced in young mice (used
for immunocapturing; EXP4–EXP6) may
depend on different factors. One of these
concerns a rapid processing of OppABp
into smaller fragments after intraperito-neal injection in mice, which may facilitate recognition of
sequences that are inaccessible in the fully folded protein
(used by the surface-oriented computational approaches).
Based on such considerations, we set out to extend the reach
of our computational prediction methods to include regions of
low accessibility in the folded protein. Both MLCE and EDP
methods are based on the analysis of the surface properties of
the protein, where accessibility and optimal antibody recognition
of certain epitopes may be limited, e.g., by steric hindrance. To
overcome this limitation, we combined the MLCE-EDP epitope
prediction strategy with a recently developed domain decompo-
sition approach that allows in silico dissection of a folded protein
into smaller fragments (Genoni et al., 2012) (see Experimental
Procedures). The underlying hypothesis is that such fragments
expose sequence stretches that may be targeted by antibodies
under conditions of partial unfolding or degradation of the
antigen protein.
Application of the domain decomposition algorithm allowed us
to identify six boundaries and cluster the results into three
different fragments: A0 (residues 83–227 and 428–507), B0 (resi-
dues 48–82, 228–302, and 528–553), and C0 (residues 303–422
and 508–527), which partially overlap with the OppABp structural
domains (Figure 4). EXP4 and EXP6 peptides are entirely con-
tained in fragments A0 and C0, respectively, whereas EXP5
extends across fragments B0 and C0.
MLCE and EDP predictions were then applied to the isolated
A0, B0, and C0 fragments, identifying potential epitopes that
very satisfactory overlap with the peptides identified by immuno-
capture. In fact, in accordance with experimental mapping, part
of the helical segment of EXP4 (consensus residues A130–R138)
was identified as a potential epitope region upon MLCE-EDP
analysis of fragment A0. Computational analysis of fragment B0
identified as a potential epitope an exposed part (consensus
Figure 2. OppABp Computational Epitope
Predictions
Consensus MLCE-EDP predictions. The left panel
is a 3D surface representation of OppABp: MLCE
(red), EDP (green), and consensus (yellow) pre-
dicted epitopes are highlighted on the surface.
Right panel is a secondary structure representa-
tion of the consensus epitope region containing
the three epitopes: COMP1, blue; COMP2, green;
and COMP3, red. These figures were produced
using VMD ver. 1.9. Figure S1 presents the results
of the MD relaxation run on OppABp crystal
structure previous to the computational epitope
predictions. Figure S2 is a visual representation
showing the MLCE and EDP predictions.
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Epitope Discovery for Structural Vaccinologyresidues Y309–K314) of EXP5, whereas analysis of the C0 frag-
ment retrieved a large portion of EXP6 and COMP2 (consensus
residues L353–P364 and T366–A370). The extended algorithm,
however, did not identify the EXP5 portion located on fragment
C0 as a possible epitope.
DISCUSSION
Structural vaccinology is a developing field that first aims to
devise viable strategies for vaccine design, based on the identi-
fication of immunogenic determinants (epitopes), through
computational and 3D structure analyses. In this context, the
crystal structure of the OppABp antigen was used as a test
case in a computational search strategy to identify epitopes, in
view of a future broader implementation in the diagnostic and
vaccine fields but also with methodological aims.
Available data regarding the immunogenic potential of
OppABp confirm that the protein is recognized by the humoral
and cell-mediated branches of the human immune response,
both known to be necessary for protection against
B. pseudomallei infection (Healey et al., 2005). OppABp is recog-
nized by antibodies present in the plasma ofmelioidosis-infected
and recovered subjects, although it did not offer protection in
preliminary studies on mice challenged with B. pseudomallei
(Felgner et al., 2009; Harland et al., 2007; Suwannasaen et al.,
2011). With regard to cell-mediated responses, OppABp is
recognized by T cells in plasma from seropositive individuals
(Tippayawat et al., 2009). The inability of recombinant OppABp
to be used in its native form in a vaccine renders it an ideal target
for structure-based engineering to foster its antigenicity.
The conformational dynamics of an antigen is a key property
in determining its immunogenic potential (Ofek et al., 2010;
Westhof et al., 1984); its characterization helps locate solvent-
accessible regions of the protein that are most likely to house
epitope regions. In this respect, MD simulations were carried
out on the crystal structure of OppABp, as a prerequisite for
subsequent computational epitope predictions. Two computa-
tional prediction methods (MLCE and EDP) were then combined,
resulting in the identification of three consensus epitopes
(COMP1–COMP3). In parallel to the computational predictions,
experimental epitope mapping was carried out on recombinant
OppABp using proteolysis, polyclonal sera from mice, and MSStructure 21, 16analysis; three epitope-carrying peptides were thus identified
(EXP4–EXP6). To assess antigenicity, all six epitopes were
synthesized as HSA-conjugated peptides and tested for anti-
body response in human plasma samples. COMP1–COMP3
and EXP4 peptides were selectively recognized by antibodies
present in plasma samples from patients that had recovered
from B. pseudomallei infection, in comparison with healthy
seronegative controls (Figure 3); notably, EXP4 and COMP1
presented very similar reactivity patterns. Human plasma
antibodies reactive versus all peptides but COMP2 were also
significantly higher in the healthy seropositive group than in the
seronegative one. In addition, plasma antibodies recognizing
EXP5–EXP6 were significantly higher in the seropositive group
than in the recovered melioidosis group, suggesting that these
peptides might find application in discriminating between
asymptomatic and symptomatic melioidosis.
A particular feature was the distinct immunoreactivity dis-
played by the synthetic COMP3 peptide, which produced
characteristic profiles in seronegative, healthy seropositive,
and melioidosis-recovered groups, suggesting its potential
use in diagnostics. Developments along these lines appear
relevant, considering that it is still very difficult to diagnose
B. pseudomallei infections due to the lack of specific symptoms.
Indeed, melioidosis is often misdiagnosed as tuberculosis,
delaying correct antibiotic treatment and thus impairing the
patients’ ability to overcome infection. As an additional point
and unexpectedly, the control recombinant OppABp was found
to be much more immunoreactive in recovered patient sera
relative to what had been reported earlier by Suwannasaen
et al. (2011). This could imply that different protein preparations
may affect the results of these studies and confirms the impor-
tance of further investigation of OppABp.
The application of MLCE-EDP methods to the OppABp crystal
structure allowed us to identify peptides COMP1–COMP3 as
potential antigens; these, however, did not match in their
sequence location the EXP4–EXP6 peptides. Because all six
peptides synthesized were recognized by human antibodies,
we conclude that they all are epitopes (or contain fragments of
OppABp epitopes). Besides the obvious consideration that every
protein hosts several distinct epitopes, the aforementioned
observation suggests that different prediction methods may
preferentially lead to the identification of different epitope7–175, January 8, 2013 ª2013 Elsevier Ltd All rights reserved 171
Figure 3. Antibody Response to
B. pseudomalleiOppABp Epitopes in Plasma
of Healthy and Recovery Melioidosis
Subjects
Crude B. pseudomallei antigen (A), recombinant
OppABp (B), and synthetic peptides COMP1 (C),
COMP2 (D), COMP3 (E), EXP4 (F), EXP5 (G), and
EXP6 (H) were coated onto ELISA plates and
probed with diluted plasma samples of healthy
seropositive individuals (S+; n = 12) tested by
means IHA (titer >40), healthy seronegative indi-
viduals (S; n = 7), and recovery melioidosis indi-
viduals (R; n = 20), and quantified by indirect
ELISA. Data represent the absorbance index (AI)
of individual samples = (OD of tested  OD of
uncoated)/OD of uncoated. Experiments were
performed in duplicate, and results represent
mean (AI) ± SE, Mann-Whitney U test; *p < 0.05,
**p < 0.01, and ***p < 0.001 values. ns, not
significant.
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Epitope Discovery for Structural Vaccinologyregions. Additionally, the multiepitope nature of any antigen may
explain the different antibody responses depending on the
progression of the disease.
The aforementioned considerations prompted us to search
for an extension of the computational methods that could
help improve the agreement between in silico predictions and
the experimental epitope mapping results. Because parts of
the experimentally identified peptides (EXP4–EXP6) were inter-
nally located in the OppABp fold, we considered that such
sequence stretches were not probed by the MLCE-EDP algo-
rithms, which exclusively focus on solvent-accessible residues.
To account for the potential exposure of internal sequence
segments under conditions of partial unfolding or degradation,
our computational approach was integrated with an energy-
based ab initio analysis designed to dissect the protein 3D
structure into smaller fragments. In such a way, sequence
stretches that are partially buried, or not optimally accessible
due to steric reasons, can be identified as possible antibody-172 Structure 21, 167–175, January 8, 2013 ª2013 Elsevier Ltd All rights reservedbinding sites. In agreement with such
theoretical considerations, consensus
epitope predictions (domain decomposi-
tion coupled to MLCE-EDP) run on the
resulting three distinct OppABp frag-
ments resulted in improved identification
of protein regions matching the experi-
mentally mapped epitopes (EXP4–EXP6)
(see Figure 4).
As a methodological speculation, we
consider that the MLCE-EDP consensus
prediction method applied to intact
antigen structure proved successful in
the design of peptides that house immu-
nogenic determinants recognized by B
cell antibodies. In a complementary way,
incorporating in silico domain fragmen-
tation of the antigenic protein, based
on rational physicochemical principles,
improved the match to epitopes experi-mentally mapped by means of murine polyclonal antibodies,
proteolysis, and immunocapturing.
The combination of all approaches reported here depicts
a successfulmethodological pipelinewith potential in a structural
vaccinology context. Among different applications, the compu-
tational part could be implemented for screening libraries of
known antigens, to generate a large, yet focused, collection of
B cell epitope predictions in a minimal time. One possible limita-
tion at this stage might be represented by the necessity of a
high-quality structure of the protein antigen. However, this
problem may be alleviated by the constant increase in the
number of experimentally solved protein structures as well as
the steady improvement in structure prediction methods.
There are several applications for antigenic peptides. For
example, with regard to melioidosis, immunization with lipopoly-
saccharide and capsular polysaccharide resulted in a delayed
mortality in mice challenged with B. pseudomallei; conjugation
to antigenic peptides from OppABp may result in increased
Figure 4. Energy-Based Domain Decompo-
sition of OppABp and Epitope Prediction
The 3D structure of OppABp is shown with the
defined fragments A0, B0, and C0 highlighted in
yellow, red, and green, respectively. The frag-
ments predicted through the decomposition
algorithm are also shown individually in the shaded
panels. The epitope regions mapped by im-
munocapture (EXP4, EXP5, and EXP6) are high-
lighted in light blue in both the full structure and in
the individual fragments. Regions of the EXP
epitopes matching those predicted by MLCE plus
EDP on the isolated fragments are shown in dark
blue and marked by arrows.
Structure
Epitope Discovery for Structural Vaccinologyprotection (Nelson et al., 2004). Because the majority of present-
day vaccines contain more than one antigen, such peptides
could also be conjugated to, or used in conjunction with, other
antigens (Purcell et al., 2007). As a final note, as for the OppABp
peptides that were recognized differently by antibodies from
healthy seropositive (EXP5–EXP6) and recovered patients
(COMP1–COMP3 and EXP4), but not by healthy seronegative
plasma, the identified antigenic peptides may provide a direct
route for the development of diagnostic tools, which in the
case of B. pseudomallei infections, remains a major unsolved
challenge.
EXPERIMENTAL PROCEDURES
Crystallization, Data Collection, Model Building, and Refinement
OppABp crystals were grown in a sitting drop setup at 20
C, in a 300 nl drop
containing 30%protein solution (5mg/ml) and reservoir solution (0.1MHEPES
[pH 7.5] and 20% PEG 8000). Crystals were cryoprotected in a solution
containing 0.1 M HEPES (pH 7.5), 25% PEG 8000, and 30% glycerol. One
crystal was used to collect X-ray diffraction data at the ID23-2 beamline at
the European Synchrotron Radiation Facility (Grenoble, France). Data were
processed using programs available from the CCP4 suite (Collaborative
Computational Project, Number 4, 1994; Evans, 2006; Leslie, 2006), and the
structure was solved by molecular replacement using Phaser (McCoy, 2007)
and the structure of OppA from Salmonella typhimurium (PDB code 1QKA)
as the search model (Sleigh et al., 1999). The structure was refined to satisfac-
tory crystallographic and geometric parameters with PHENIX.refine, under the
PHENIX platform (Adams et al., 2010; Afonine et al., 2010; Chen et al., 2010;
Emsley and Cowtan, 2004; Murshudov et al., 1997) (Table 1). Additional details
are provided in the Supplemental Experimental Procedures. Atomic coordi-
nates and structure factors have been deposited in the Protein Data Bank
(http://www.rcsb.org/pdb), under accession code 3ZS6 (Berman et al., 2000).Structure 21, 167–175, January 8, 2013Epitope Prediction and Design
The crystal structure of OppABp was used as
a starting point for a 30 ns all-atom MD simulation
in explicit water at 300 K. The simulations and the
analysis of the trajectories were performed using
the GROMACS 4.5.1 software package (Hess
et al., 2008), GROMOS96 force field (van Gunste-
ren et al., 2006), and the SPC water model (Be-
rendsen et al., 1987). The procedure employed is
fully described in Supplemental Experimental
Procedures.
MLCE Method
Epitope predictions were carried out on the repre-
sentative structure of the most populated struc-
tural cluster obtained using the method developed
by Daura et al. (1999). The MLCE method (Scara-belli et al., 2010) is based on the eigenvalue decomposition of the matrix of
residue-residue energy couplings (Colacino et al., 2006a, 2006b; Morra and
Colombo, 2008; Ragona et al., 2005; Tiana et al., 2004) (see Supplemental
Experimental Procedures), available as the free web tool BEPPE (http://
bioinf.uab.es/BEPPE).
EDP Method
In order to increase the consistency of the epitope predictions, the MLCE
output was crossed with the EDP output for consensus surfaces. The EDP
method calculates the free energy penalty for desolvation placing a neutral
probe at various protein surface positions. Surface regions with a small free
energy penalty for water removal may correspond to preferred interaction
sites. Evidence suggests that it is easier for an antibody to bind to an epitope
when properties required for high-affinity binding like low desolvation penalty
are met (Fiorucci and Zacharias, 2010).
Epitope Identification Based on MLCE-EDP Consensus
The final predicted epitopes, which represent the sequences chosen for
peptide synthesis, were obtained from the consensus results of the two
predictions. From sequence alignments, we selected the corresponding over-
lapping regions, whichwere defined as candidate epitopes (COMP1–COMP3).
The candidate epitopes were produced via solid-phase synthesis as reported
below.
Epitope Mapping with Murine Sera
Peptide mixtures were obtained by trypsin digestion in 50 mM ammonium
bicarbonate buffer at a ratio of 10:1, at 37C for 3 hr. To capture the
epitope-containing peptide, a 25 ml suspension of Dynabeads Pan Mouse
IgG (uniform, superparamagnetic polystyrene beads of 4.5 mm diameter
coated with monoclonal human anti-mouse IgG antibodies) was used. The
beads were washed twice with PBS using a magnet and resuspended in the
initial volume. A total of 50 ml of the murine serum, prepared as described in
Supplemental Experimental Procedures, was added and incubated for
30 min at room temperature (RT), after which the beads were washed fiveª2013 Elsevier Ltd All rights reserved 173
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Epitope Discovery for Structural Vaccinologytimes with PBS to remove serum debris. A total of 0.5 ml of Protease Inhibitor
Mix (GE Healthcare) was added before the peptide mixture to avoid potential
antibody degradation. The sample was then incubated for 2 hr at RT with
gentle tilting and rotation. After incubation, beads were washed three times
with 1 ml PBS, and the bound peptides were eluted in 50 ml of 0.2% TFA.
The elute fraction was concentrated and washed with C18 ZipTips (Millipore)
and eluted in 2 ml of 50%ACN and 0.1% TFA. Subsequent MALDI-MS analysis
of the eluted fractions was carried out as described in the Supplemental
Experimental Procedures.
Synthesis of Epitope Peptides
In view of their use as immunogens to generate antibodies, the original COMP
peptides were elongated by including two flanking residues at the N and
C termini, based on the consideration that longer sequences induce better
immunogenic responses (Purcell et al., 2007). PEG moieties (MW 308.16)
were introduced at the N terminus of each peptide (COMP1–COMP3 and
EXP4–EXP6) as spacers for subsequent immunological tests. A cysteine
residue preceded the PEG group to facilitate conjugation to HSA, the carrier
protein. All peptides were prepared in free- and HSA-conjugated forms.
COMP1 is a discontinuous conformational epitope composed of two short
peptides that are brought close together in the tertiary structure. Measurement
of the average distance between the termini of COMP1 from MD simulations
suggested that insertion of two glycine residues would be sufficient to bridge
the two short sequences.
Indirect ELISA to Detect Antibodies to B. pseudomallei
Antibody recognition of the peptides was detected using indirect ELISA using
96-well microtiter plates (Nunc; MaxiSorp) that were uncoated or coated with
50 ml/well of 3 mg/ml crudeB. pseudomallei-extracted antigens (Crude Bps), or
10 mg/ml of recombinant OppABp as controls, or 3 mg/ml peptides COMP1,
COMP2, COMP3, EXP4, EXP5, and EXP6 in 0.1 M carbonate-bicarbonate
buffer (pH 9.6), incubating at 37C for 3 hr. Immunoreactivity was revealed,
probing the plates with 1:300 diluted plasma samples from healthy and
recovery melioidosis subjects. See Supplemental Experimental Procedures
for details of the procedure and human plasma sample preparation.
Domain Mapping and Cleavage Site Prediction
Domain mapping was performed using a newly developed ab initio computa-
tional method by Genoni et al. (2012) (see Supplemental Experimental Proce-
dures). This technique is an expansion of the energy decomposition method
(Tiana et al., 2004), which diagonalizes the protein-nonbonded interaction
energy matrix Enb (namely, van der Waals and electrostatics) to identify the
amino acids necessary for the stabilization of the protein fold from the eigen-
vector associated with the lowest eigenvalue.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.str.2012.10.005.
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